What can the pharmaceutical industry learn from Netflix?
Four years after its initial EU market authorisation, NICE recommended Celgene’s Revlimid® as a first-line treatment in...
Contributors
-
Account Manager -
President, USA -
-
Publications Executive -
Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
Chief Commercial Officer -
US CEO -
Senior Consultant -
Associate Editorial Director -
Sr. Research Analyst -
Principal -
Research Executive -
Account Director -
Consultant -
Vice President -
Head of MedErgy (CH-MedErgy) -
Project Manager -
Project Manager -
Managing Consultant -
Senior Consultant -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- May 2019 (7)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
Brain-controlled hearing aids could cut through crowd noise
I've been bilaterally profoundly deaf since I was 18 months old (an unfortunate side effect of a severe bacterial meningitis infection I...
What is your digital strategy? The Novartis /Sandoz approach
Digital strategy in healthcare as part of the wider digital health environment is coming more and more into focus at the large...
Big Pharma needs a new model for R&D for less wealthy markets
Kenan Malik wrote an opinion piece in the Guardian this week (Sunday 5th May) that summarized a key problem facing R&D in pharma;...
Combination Failures & Futures—Much Ado About What?
For all the successes that the checkpoint inhibitors (CPIs) have had over the past 8 years since their first approvals, and all the...
On the Transformative Potential of Advanced Therapeutics in Rare Disease
The burgeoning field of cell and gene therapies collectively referred to as Advanced Therapeutics (ADVTX), is at last beginning to...
8 challenges for Cell and Gene Therapies
I have just attended a panel discussion at Bio Trinity 2019 and thought it was worth summarising the challenges the panellists described...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net